Literature DB >> 400999

Depressive symptoms in acute schizophrenia.

S M Montgomery1.   

Abstract

1. The incidence of psychopathological symptoms rated by the CPRS was compared in 54 English depressed patients and 52 Swedish depressed patients. 2. A new rating scale for depression was created from the 10 items shown to be most sensitive to treatment change. The Montgomery and Asberg Depression Rating Scale (MADRS) was found to be more sensitive to treatment change than the Hamilton Rating Scale (HRS). 3. The incidence of psychopathological symptoms was assessed using the full Comprehensive Psychopathological Rating Scale (CPRS) in 50 patients with unequivocal acute schizophrenia. 36 patients were rated again after treatment and a 12 item rating scale for schizophrenia was derived from the items best able to discriminate between responders and non responders. 4. The schizophrenia scale was found to be a more sensitive discriminator between responders and non responders than the Brief Psychiatric Rating Scale (BPRS) in the 25 patients rated on both scales simultaneously. 5. There was a relatively high incidence of depressive symptoms rated on the MADRS in acute schizophrenia suggesting that depressive symptoms are a commoner presenting feature of acute unequivocal schizophrenia than is normally acknowledged.

Entities:  

Mesh:

Year:  1979        PMID: 400999     DOI: 10.1016/0364-7722(79)90058-4

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol        ISSN: 0364-7722


  12 in total

Review 1.  Depression in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

2.  Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder.

Authors:  Alberto Chiesa; Concetta Crisafulli; Stefano Porcelli; Changsu Han; Ashwin A Patkar; Soo-Jung Lee; Moon Ho Park; Tae-Youn Jun; Alessandro Serretti; Chi-Un Pae
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-05       Impact factor: 5.270

3.  Low-dose transdermal testosterone augmentation therapy improves depression severity in women.

Authors:  Karen K Miller; Roy H Perlis; George I Papakostas; David Mischoulon; Dan V Losifescu; Danielle J Brick; Maurizio Fava
Journal:  CNS Spectr       Date:  2009-12       Impact factor: 3.790

4.  A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up.

Authors:  John F M Gleeson; Sue M Cotton; Mario Alvarez-Jimenez; Darryl Wade; Donna Gee; Kingsley Crisp; Tracey Pearce; Daniela Spiliotacopoulos; Belinda Newman; Patrick D McGorry
Journal:  Schizophr Bull       Date:  2011-11-29       Impact factor: 9.306

Review 5.  [Diagnostics and multimodal treatment of depression in old age : New developments].

Authors:  Gerhard W Eschweiler
Journal:  Z Gerontol Geriatr       Date:  2017-01-19       Impact factor: 1.281

6.  Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia.

Authors:  Deepak Cyril D'Souza; Irina Esterlis; Michelle Carbuto; Maegan Krasenics; John Seibyl; Frederic Bois; Brian Pittman; Mohini Ranganathan; Kelly Cosgrove; Julie Staley
Journal:  Am J Psychiatry       Date:  2012-03       Impact factor: 18.112

7.  Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia.

Authors:  Douglas L Boggs; Toral S Surti; Irina Esterlis; Brian Pittman; Kelly Cosgrove; R Andrew Sewell; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Schizophr Res       Date:  2017-04-06       Impact factor: 4.939

8.  6 Weeks Monotherapy with Antipsychotic Drug Reduced Inflammatory Markers in Bipolar Disorder Patients.

Authors:  Marco Ferrari; Marco Godio; Camilla Callegari; Marco Cosentino; Franca Marino
Journal:  Psychopharmacol Bull       Date:  2022-05-31

9.  Pancreatic cancer and depression: myth and truth.

Authors:  Martina Mayr; Roland M Schmid
Journal:  BMC Cancer       Date:  2010-10-20       Impact factor: 4.430

10.  Social functioning trajectories of young first-episode psychosis patients with and without cannabis misuse: a 30-month follow-up study.

Authors:  César González-Blanch; John F Gleeson; Peter Koval; Sue M Cotton; Patrick D McGorry; Mario Alvarez-Jimenez
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.